返回首页 用户名: 密 码: 认证码: 9982    药师会员  单位会员    注册找回密码?
设为首页
加入收藏
最新文章

顺丰欲搅局医药物流 行业“...

骆抗先:打干扰素需要同时用...

国家医保局开会了!传递重要...

过期药品回收机制还缺点“料”

基于数据挖掘的《理虚元鉴》...

基于分子对接技术的金莲花主...

京、津、冀三地中药炮制规范...

关于贝伐珠单抗注射液生物类...

药学专题
用药安全之用药错误专题

用药错误是指药物使用过程中发生的..

关注儿童合理用药

关爱老人“药”知道!

用药安全之用药错误专题

“中国造”假药行销全球

     药学部舞蹈《开门红》喜获我院新春文艺晚会三等奖 龙载硕果辞旧岁,蛇舞祥和迎新春。1月25日下午三点,,“芜湖市第一人民医院新春联欢会”在医院十楼多功能厅隆重举行。药学部为联欢会赶排了开场歌舞《开门红》,获得了评委、领导和观众的一致好评,引来观众热烈掌声,最终获得了三等...
当前位置:首页 >> 合理用药 >> 药学服务
依那西普保留模式和停止治疗相关因素
文章来源:中华风湿    添加人:芜湖市中医医院药剂科    添加时间:2017/7/28 15:02:56

背 景

        依那西普是可溶性肿瘤坏死因子(TNF)受体(人工蛋白),用以治疗免疫介导性炎症疾病,如类风湿性关节炎(RA)、银屑病关节炎(PsA)、强直性脊柱炎(AS)和银屑病(PsO)。在加拿大现实情况中,影响是否使用依那西普以及长期保持使用该药物的因素的信息十分有限。

目 的

        测定加拿大的患者在六年时间内依那西普的保持使用率,并确定与停药相关的影响因素。

方 法

        本研究为回顾性队列研究,采用了昆泰药业自费医疗药物数据库(PDP)、安大略公费医疗药物数据库(OPDP)以及魁北克公费医疗药物数据库(RAMQ)的纵向处方药报销数据,对在2008年7月至2010年6月间初次开始使用依那西普的患者进行身份认证并进行为期72个月的跟踪研究。分别在第一年、第二年、第三年、第四年和第五年评估保持治疗的患者的12个月保持使用率,并与第一年的保持使用率进行对比。研究利用Cox比例风险模式确定在这72个月期间,与停止用药的时间点相关的协变量。

结 果

        本研究确认在选定期间内,加拿大共有4528名使用依那西普的患者(61%为女性,85%患有风湿性疾病,15%患有牛皮癣)开始接受治疗。总体而言,在沿用第一年治疗方案的患者中依那西普12个月保持使用率显著升高(p<.0001),第一年的12个月保持使用率为66%,第二年为79%,第三年为82%,第四年为84%,第五年为83%,而第六年为79%。共有17.1%(n=771)的患者在72个月的研究期间内都保持使用依那西普。回归分析显示,相比于其他患者,牛皮癣患者的保持使用率较低(HR1.199;p<.0001),老年患者(65岁以上)的保持使用率比年轻患者高(HR 0.802;p<.0001),而公费医疗患者的保持使用率比比自费医疗患者高(ODB HR 0.735,RAMQ HR 0.55;p<.0001)。

结 论

        患者保持使用依那西普的可能性随着患者维持治疗年限的增加而增加。这一模式适用于各治疗领域、性别、年龄及医疗付费模式。研究发现,年龄、病症及医疗付费模式对患者决定停止治疗的时间点有显著影响。在对与保持使用率相关因素作进一步研究后,可以在支持高风险患者群体接受稳定的治疗的同时,根据他们的具体需求有针对性地设计资助方案。

原 文

Etanercept retention patterns and factors associated with treatment discontinuation: a retrospective cohort study using canadian claims-level data

        M Khraishi1, Y Zhang2, J Ivanovic2, B Millson2, M-J Brabant2, K Charland2, E Singh3, J Woolcott4, H Jones3

        Citation

        VomeroM,CapozziA,BarbatiC, et al

        FRI0028 In vitro inhibitory effect of etanercept on autophagy: a new mechanism of action of tnf inhibitors in rheumatoid arthritis

        Annals of the Rheumatic Diseases2017;76:490.

        Publication history

        Published in print1 June 2017.

        Published online15 June 2017.

ABSTRACT

Background

        Etanercept is a soluble TNF receptor (humanized protein) indicated for the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and psoriasis (PsO). Limited information exists on the factors associated with long-term retention and use of etanercept in Canada in a real-world setting.

Objectives

        To evaluate the 6-year retention rates of etanercept patients in Canada, and to identify factors associated with discontinuation.

Methods

        A retrospective cohort study was conducted using longitudinal prescription drug claims data from QuintilesIMS Private Drug Plan database (PDP), Ontario Public Drug Plan database (OPDP), and Quebec Public Drug Plan database (RAMQ). Between 07/2008 and 06/2010, bio-naïve patients who initiated etanercept were identified and followed for 72 months. 12-month retention rates were evaluated in 1-year increments for all patients retained on therapy at years 1, 2, 3, 4 and 5 and compared to retention rates in the first year. The covariates associated with time to discontinuation over the entire 72 month period were identified using a Cox proportional hazards regression model.

Results

        The study identified 4,528 etanercept patients (61% female, 85% rheumatic diseases, and 15% PsO) across Canada who started their therapy during the selection period. Overall, 12-month retention rates on etanercept increased significantly for patients following their first year on therapy (p<.0001), with 66% of patients retained at year 1 vs. 12- month retention rates of 79%, 82%, 84%, 83% and 79% at year 2, 3, 4, 5 and 6, respectively. A total of 17.1% (n=771) of patients were retained for the entire 72 month study. Regression analysis showed PsO patients were less likely to be retained on therapy than other indications (HR 1.199; p<.0001), older patients (65+) were more likely to be retained than younger patients (HR 0.802; p<.0001), and public plan patients (ODB HR 0.735, RAMQ HR 0.55; p<.0001) were more likely to be retained than private plan patients.

Conclusions

        Etanercept patient retention likelihood increased the more years a patient was retained on therapy. This pattern was consistent across therapeutic areas, sex, age, and payers. Age, indication, and payer were found to have a significant impact in determining etanercept patients' time to therapy discontinuation. With better understanding of factors associated with retention, patient support programs can be designed to address the specific needs of at-risk groups while supporting patients stable on therapy.



分享到:


(声明:本网站所有文章均由发布单位自行发布,仅供专业学术交流。如果您认为有的文章侵犯了您的版权或其他权利,请及时与发布单位联系,以便立即更正。同时,其他网站对本站内容进行复制、转摘,也请注明出处。) 
相关新闻

关于我们 | 经典案例 | 联系我们 | 宣传合作 | 付款方式 | 使用帮助 | 招聘精英

药学之窗 版权所有 Copyright © 2004-2015 All Rights Reserved.
网站邮箱:WinPharm@126.com 联系电话:0553-3288518 3816058
声明:网站内容仅供学术交流和参考,不作为医疗诊治的依据
网站备案:皖ICP备10206150号-5